Table 1

Clinical characteristics of the brain, breast, ovary and prostate tumor samples, and three breast cancer cell lines used for BAC library construction

Library name


AA9

B421

CHORI-514

MCF7

PM-1

CHORI-510

CHORI-518

CHORI-520


Clinical sample designation

AA9

B421

S104

MCF-7

25-48

860-7

BT-474

SK-BR-3

Organ site

Brain

Breast

Breast

Breast cancer adenocarcinoma (metastasis - pleural effusion)

Prostate metastasis

Ovarian carcinoma

Ductal carcinoma

Breast cancer adenocarcinoma (metastasis - pleural effusion)

Therapies applied

Radiotherapy

Chemotherapy 4 months before surgery (CMF)

No radiation therapy or chemotherapy before surgery

N/A

Hormone ablation, palliative radiotherapy

No therapy before surgery

N/A

N/A

Patient status

Deceased

Deceased, no recurrence

No recurrence for 10 years

N/A

Deceased

Tumor recurred within 13 months

N/A

N/A

Total amount of tumor material used for library construction (mg)

100

150 (20 mg effective)

100

N/A

50

200

N/A

N/A

Average clone size (± standard deviation; kb)

129.1 ± 38.3

136.4 ± 29.2

166.1 ± 53.2

148.0 ± 30

N/D

149.3 ± 28.8

179 ± 23

154 ± 25


Shown are the clinical characteristics of the recurrent glioblastoma AA9, primary breast tumors B421 and S104, ovarian tumor 860, prostate metastasis 25-48, and the breast cancer cell lines MCF7, BT474, and SKBR3 used for bacterial artificial chromosome (BAC) library construction. Average clone size was determined by pulsed field-gel electrophoresis of Not1-digested DNA from 30 to 100 clones. The presence of a large blood clot in the B421 sample reduced the effective amount of tumor tissue to an estimated 20 mg (out of about 150 mg received from the tumor bank). CMF, cyclophosphamide, methotrexate and fluorouracil; kb, kilobases; N/A, number is not applicable for cell lines that can be grown in any amount and whose clinical history is not available; N/D, number not determined.

Raphael et al. Genome Biology 2008 9:R59   doi:10.1186/gb-2008-9-3-r59

Open Data